Iovance Biotherapeutics is trading 8.85% lower at $13.50, compared with its October 28 close of $14.81; available news does not establish a clear reason for the decline.
- The company announced positive Phase 2 lifileucel results in previously treated nonsquamous metastatic lung cancer.
- Iovance scheduled an 8:30 a.m. ET webcast for October 29. The positive news does not explain the reported decline.